Information  X 
Enter a valid email address

Thomson Reuters (TRIL)

  Print      Mail a friend

Tuesday 29 April, 2008

Thomson Reuters

New Thomson Reuters Biomarkers Report Shines a ...





PHILADELPHIA and LONDON, April 29 /PRNewswire/ --

    - Biomarkers to Open the Door to Personalized Medicine and Represents a
Seismic Shift for the Pharma Industry



    The Scientific business of Thomson Reuters today announced the launch of
a new biomarkers report, "Establishing the Standards in Biomarker Research"
which gives a detailed introduction to the world of biomarkers, an overview
of the regulatory context surrounding them, and highlights ongoing biomarker
research in some of the world's leading Pharma companies.



(Logo: http://www.newscom.com/cgi-bin/prnh/20080424/NYTH069LOGO )

    Thomson Reuters has chosen to highlight advances in biomarker research
because of its capacity to change the way Pharma companies do business.
Biomarkers which are blood-based tests, gene sequences or mutations, mRNA
expression profiles or tissue proteins, provide unparalleled evidence of the
state of an organism, or indicate normal biological processes, pathogenic
processes or pharmacological responses to a therapeutic intervention.



    "Biomarkers seem destined to prove one of the major drivers of
pharmaceutical research and drug development in the 21st century," said Jon
Brett-Harris, EVP Pharmaceutical and Chemicals Markets, Thomson Reuters. "For
example, the presence of a specific antibody in the blood might indicate a
specific infection. Once an association between a biomarker and a disease is
clearly established, the one can be used to signal the other, and to a high
degree of certainty. As well, changes in the prevalence of a biomarker in the
organism can immediately and reliably signpost a patient's response to
treatment."



    Some pharmaceutical companies are already advancing their research and
harnessing the power of biomarkers, which can:


    
    -- Be used to detect the predisposition for disease in a population,
       screen for its presence, confirm its diagnosis, assess its severity,
       predict its response to available therapies and measure its
       clinical course
    -- Be used as targets to discover new drugs
    -- Be a decisive factor in determining whether or not to continue
       research on an entity
    -- Show early in the development phase whether an entity could lead to
       side effects that should terminate further research
    -- Help to make clinical trials more efficient
    -- Reduce treatment overheads by optimizing dosages and measuring a
       patient's response more quickly and accurately


    It is believed that every drug process may have a number of biomarkers
associated with it. Most scientists already use a core set of biomarkers, but
this is insignificant when compared to the thousands of biomarkers that may
exist and have yet to be discovered, documented or quantified. The new
Thomson Reuters biomarker report suggests that the disease areas at the
forefront of the drive to discover new biomarkers are: cancer, cardiology,
neurology, and metabolic, autoimmune and inflammatory diseases.



    However, although biomarkers represent the future of drug development,
Thomson Reuters analysis has found broad differences in the Pharma industry's
approach to them. Some innovators have important biomarker research projects
progressing, while many others have yet to attempt any research at all.



    In spite of this, biomarkers are clearly at the top of the agenda for
regulatory authorities. The FDA has recognized that biomarkers are an area of
supreme importance to pharmaceutical innovation and personalized medicine and
is seeking to create a new framework for regulatory acceptance. Other
agencies, including the EMEA, are engaging with same process. In Japan, the
Ministry of Education, Culture, Sports, Science and Technology, and the
Ministry of Health, Labor and Welfare, have proposed biomarker development as
a national project, and are actively promoting biomarker research.



    To read the full report, "Establishing the Standards in Biomarker
Research", please register online at:
http://scientific.thomson.com/forms/biomarkers/



    The Scientific business of Thomson Reuters provides information and
knowledge to accelerate research, discovery and innovation. Its
authoritative, accurate and timely information is essential for drug
companies to discover new drugs and get them to market faster; researchers to
find relevant papers and know what's newly published in their subject; and
businesses to optimize their intellectual property and find competitive
intelligence. We create the research platforms and services of the future
that will power our customers toward business and personal success.



About Thomson Reuters

    Thomson Reuters is the world's leading source of intelligent information
for businesses and professionals. We combine industry expertise with
innovative technology to deliver critical information to leading decision
makers in the financial, legal, tax and accounting, scientific, healthcare
and media markets, powered by the world's most trusted news organization.
With headquarters in New York and major operations in London and Eagan,
Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries.
Thomson Reuters shares are listed on the New York Stock Exchange (NYSE: TRI);
Toronto Stock Exchange (TSX: TRI); London Stock Exchange (LSE: TRIL); and
Nasdaq (NASDAQ: TRIN). For more information, go to www.thomsonreuters.com.


    
    CONTACTS
    Eoin Bedford
    PR Manager
    Scientific
    +44-(0)207-433-4691
    eoin.bedford@thomsonreuters.com

    Web site: http://www.thomsonreuters.com
              http://scientific.thomson.com/forms/biomarkers